Welcome to the latest edition of “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. HEALTHCARE ...

Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.

The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.

Amgen said yesterday that its cholesterol-lowering injection Repatha cut the risk of a composite of heart disease death, heart attacks, and strokes in a 12,000-patient trial, bolstering hopes for ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients without prior cardiovascular disease, for which the drug was approved in ...

Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...

Amgen (AMGN) stock is in focus as its cholesterol drug Repatha succeeds in a Phase 3 trial, reducing the risk of major adverse cardiovascular events. Read more here.

The Trump administration asked the high court to block an injunction that allows applicants to self-select the sex designation on their passports. (Jenny Kane / AP file) The Trump administration has ...